Skip to main content
SpringerLink
Log in

Ibrutinib increases risk of AF, HF and haemorrhage

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Abdel-Qadir H, et al. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. Journal of Clinical Oncology : 31 Aug 2021. Available from: URL: http://doi.org/10.1200/JCO.21.00693

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ibrutinib increases risk of AF, HF and haemorrhage. Reactions Weekly 1872, 9 (2021). https://doi.org/10.1007/s40278-021-01935-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-01935-y

Search

Navigation